Graft Versus Host Disease (GvHD) Treatment Market Outlook, 2024-2028 & 2033 - Revenue Shares for Corticosteroids, Monoclonal Antibodies, Immunosuppressants and Other Products
10 déc. 2024 09h45 HE
|
Research and Markets
Dublin, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This GvHD treatment...
Cryoglobulinemic Vasculitis Market is Forecasted to Reach $930.1 Million by 2034, Growing at 6.9% CAGR | Fact.MR Report
12 nov. 2024 07h30 HE
|
FACT.MR
Rockville, MD, Nov. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Cryoglobulinemic vasculitis market is estimated to reach a...
Immunomodulators Global Business Analysis Report 2024-2030: Growing Focus on Combination Therapies Enhances Market Opportunities, Increased Focus on Developing Targeted Therapies
07 nov. 2024 10h43 HE
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Immunomodulators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immunomodulators...
Graft Versus Host Disease (GvHD) Treatment Industry Forecast Report, 2024-2032 - Global Market Size Forecast to Double, with Emerging Markets Offering Substantial Growth Potential
07 nov. 2024 09h47 HE
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The graft...
Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h57 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Post-Transplant Lymphoproliferative Disorder Drug Pipeline Market Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
22 oct. 2024 09h53 HE
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Post-Transplant Lymphoproliferative Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
Immunosuppressants Research Report 2023-2024 & 2030: Healthcare Focus on Targeted, Patient-Centric Treatments Spurs Multi-Billion Dollar Growth Amid Rising Organ Transplants and Autoimmune Diseases
15 oct. 2024 09h37 HE
|
Research and Markets
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Immunosuppressants - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Etanercept Biosimilar Insight Market Report 2024: Pipeline Analysis, Therapeutic Assessment, Sales Assessment, Unmet Needs, and Impact of Drugs
19 sept. 2024 10h21 HE
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Etanercept - Biosimilar Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This "Etanercept - Biosimilar Insight, 2024" report...
Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications
27 juin 2024 09h43 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
Acute Graft-Versus-Host Disease Pipeline Research 2024 Featuring MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, and Incyte
26 juin 2024 09h34 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Graft-Versus-Host Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Acute...